First-line treatment selection in HER2-mutant NSCLC balances route of administration, efficacy data by mutation subtype, and ...
Although it may take time for physicians to become used to this regimen, there is greater urgency now that it can be given ...
Preliminary findings were presented at the 2025 ASCO Genitourinary Cancers Symposium. 2 Investigators reported that 71% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results